| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mabrouk El-Sabagh, Dai Taniguchi, Toshihisa Sugino, Taketo Obits. Metabolomic profiling reveals differential effects of glucagon-like peptide-1 and insulin on nutrient partitioning in ovine liver. Animal science journal = Nihon chikusan Gakkaiho. vol 87. issue 12. 2017-03-16. PMID:26991154. |
four suffolk wethers (60.0 ± 6.7 kg body weight (bw)) were used in a repeated-measure design under euglycemic--hyperinsulinemic and hyper -glp-1 clamps for 150 min with intravenous infusion of insulin (0.5 mu/kg bw/min; from 0 to 90 min), glp-1 (0.5 µg/kg bw/min; from 60 to 150 min) and both hormones co-administered from 60 to 90 min. |
2017-03-16 |
2023-08-13 |
Not clear |
| Mabrouk El-Sabagh, Dai Taniguchi, Toshihisa Sugino, Taketo Obits. Metabolomic profiling reveals differential effects of glucagon-like peptide-1 and insulin on nutrient partitioning in ovine liver. Animal science journal = Nihon chikusan Gakkaiho. vol 87. issue 12. 2017-03-16. PMID:26991154. |
liver biopsies were collected at 0, 60, 90 and 150 min to represent the metabolomic profiling of baseline, insulin, insulin plus glp-1, and glp-1, respectively, and were analyzed for metabolites using capillary electrophoresis time-of-flight mass spectrometer. |
2017-03-16 |
2023-08-13 |
Not clear |
| Mabrouk El-Sabagh, Dai Taniguchi, Toshihisa Sugino, Taketo Obits. Metabolomic profiling reveals differential effects of glucagon-like peptide-1 and insulin on nutrient partitioning in ovine liver. Animal science journal = Nihon chikusan Gakkaiho. vol 87. issue 12. 2017-03-16. PMID:26991154. |
metabolomics analysis reveals 51 metabolites as being significantly altered (p < 0.05) by insulin and glp-1 infusion compared to baseline values. |
2017-03-16 |
2023-08-13 |
Not clear |
| Bilal Omar, Linda Ahlkvist, Yuchiro Yamada, Yutaka Seino, Bo Ahré. Incretin hormone receptors are required for normal beta cell development and function in female mice. Peptides. vol 79. 2017-03-13. PMID:27020250. |
the incretin hormones, glucose dependent insulinotropic polypeptide (gip) and glucagon-like peptide 1 (glp-1), potentiate insulin secretion and are responsible for the majority of insulin secretion that occurs after a meal. |
2017-03-13 |
2023-08-13 |
mouse |
| D Cimmaruta, M I Maiorino, C Scavone, L Sportiello, F Rossi, D Giugliano, K Esposito, A Capuan. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert opinion on drug safety. vol 15. issue sup2. 2017-03-10. PMID:27875915. |
areas covered: when glycemic levels are not adequately controlled, an association of glp-1 receptor agonists and insulin therapy can be adopted. |
2017-03-10 |
2023-08-13 |
Not clear |
| D Cimmaruta, M I Maiorino, C Scavone, L Sportiello, F Rossi, D Giugliano, K Esposito, A Capuan. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert opinion on drug safety. vol 15. issue sup2. 2017-03-10. PMID:27875915. |
in 10 studies, glp-1 receptor agonists were added on to an existing regimen, whereas insulin added to an existing glp-1 receptor agonists regimen occurred in 2 studies. |
2017-03-10 |
2023-08-13 |
Not clear |
| D Cimmaruta, M I Maiorino, C Scavone, L Sportiello, F Rossi, D Giugliano, K Esposito, A Capuan. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert opinion on drug safety. vol 15. issue sup2. 2017-03-10. PMID:27875915. |
six studies compared glp-1 receptor agonists with short acting insulin as a treatment strategy to intensify basal insulin therapy. |
2017-03-10 |
2023-08-13 |
Not clear |
| D Cimmaruta, M I Maiorino, C Scavone, L Sportiello, F Rossi, D Giugliano, K Esposito, A Capuan. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review. Expert opinion on drug safety. vol 15. issue sup2. 2017-03-10. PMID:27875915. |
expert opinion: clinical trials herein reviewed demonstrated the safety and the efficacy of combining glp-1 receptor agonists with basal insulin, with most studies showing equal or slightly superior efficacy, as compared with the addition of prandial insulin, associated with weight loss and less hypoglycemia. |
2017-03-10 |
2023-08-13 |
Not clear |
| E Sélley, S Kun, I A Szijártó, M Kertész, I Wittmann, G A Molná. Vasodilator Effect of Glucagon: Receptorial Crosstalk Among Glucagon, GLP-1, and Receptor for Glucagon and GLP-1. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. vol 48. issue 7. 2017-03-06. PMID:26975347. |
glucagon causes dose-dependent relaxation in the rat thoracic aorta, which is as potent as that of insulin but greater than that of glp-1 (7-36) amide. |
2017-03-06 |
2023-08-13 |
rat |
| Linda Ahlkvist, Bilal Omar, Giovanni Pacini, Bo Ahré. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice. European journal of pharmacology. vol 780. 2017-03-06. PMID:26997369. |
atropine did also not affect the augmentation by glp-1 and gip on glucose-stimulated insulin secretion from isolated islets. |
2017-03-06 |
2023-08-13 |
mouse |
| Linda Ahlkvist, Bilal Omar, Giovanni Pacini, Bo Ahré. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice. European journal of pharmacology. vol 780. 2017-03-06. PMID:26997369. |
based on these findings, we suggest that muscarinic mechanisms contribute to the stimulation of insulin secretion by dpp-4 inhibition through neural effects induced by glp-1 and gip whereas neural effects do not affect the levels of glp-1 or gip or the islet effects of the two incretin hormones. |
2017-03-06 |
2023-08-13 |
mouse |
| Karen Ekkelund Petersen, Günaj Rakipovski, Kirsten Raun, Jens Lykkesfeld. Does Glucagon-like Peptide-1 Ameliorate Oxidative Stress in Diabetes? Evidence Based on Experimental and Clinical Studies. Current diabetes reviews. vol 12. issue 4. 2017-03-03. PMID:26381142. |
well-known effects of glp-1 including better glycemic control, decreased food intake, increased insulin release and increased insulin sensitivity may indirectly contribute to this phenomenon, but glucose-independent effects on ros level, production and antioxidant capacity have been suggested to also play a role. |
2017-03-03 |
2023-08-13 |
Not clear |
| Xueying Tan, Jingbo H. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy. vol 17. issue 9. 2017-03-03. PMID:27156529. |
dipeptidyl peptidase-4 (dpp-4) inhibitors are novel, potent oral antihyperglycemic agents that reduce degradation of endogenous glucagon-like peptide 1 (glp-1) to increase insulin secretion and satiety and decrease glucagon. |
2017-03-03 |
2023-08-13 |
Not clear |
| Fei Wang, Liang Zhou, Xiudao Song, Guoqiang Liang, Heng Xu, Lurong Zhang, Guorong Jian. Acute Reduction of Incretin Effect and Glucose Intolerance in Rats by Single Intragastric Administration of 3-deoxyglucosone. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. vol 125. issue 1. 2017-03-03. PMID:27658000. |
in this study, to examine the acute effects of single intragastric administration of 3dg at dose of potentially single-meal intake on plasma glucose, insulin, glucagon, total glp-1 and total gip levels in response to a glucose load, ogtt was performed immediately in normal kunming mice or sprague-dawleys rats after 3dg administration. |
2017-03-03 |
2023-08-13 |
mouse |
| Song-Tao Tang, Huan Su, Qiu Zhang, Hai-Qin Tang, Chang-Jiang Wang, Qing Zhou, Wei Wei, Hua-Qing Zhu, Yuan Wan. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. International journal of molecular medicine. vol 37. issue 6. 2017-02-28. PMID:27122056. |
the serum levels of et-1, no, glp-1 and insulin were measured as well as endothelial function. |
2017-02-28 |
2023-08-13 |
rat |
| Markolf Hanefeld, Denis Raccah, Louis Monnie. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus. Expert opinion on drug metabolism & toxicology. vol 13. issue 3. 2017-02-27. PMID:27776453. |
the combination of a short-acting glp-1 ra, such as lixisenatide, with a basal insulin, exploits the complementary effects of both of these therapies and seems well suited for the treatment of t2dm. |
2017-02-27 |
2023-08-13 |
Not clear |
| Suleman Chaudhry, Marilia Bernardes, Paul E Harris, Antonella Maffe. Gastrointestinal dopamine as an anti-incretin and its possible role in bypass surgery as therapy for type 2 diabetes with associated obesity. Minerva endocrinologica. vol 41. issue 1. 2017-02-23. PMID:26505694. |
we propose that da and glucagon-like peptide 1 (glp-1) represent two opposing arms of a glucose stimulated insulin secretion (gsis) regulatory system and hypothesize that dopamine represents the "anti-incretin" hypothesized to explain the beneficial effects of bariatric surgery on t2dm. |
2017-02-23 |
2023-08-13 |
Not clear |
| Thomas Fors. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus. Expert opinion on pharmacotherapy. vol 17. issue 12. 2017-02-22. PMID:27341040. |
one such agent that can be administered in combination with basal insulin is the glucagon-like peptide-1 receptor agonist (glp-1 ra) lixisenatide. |
2017-02-22 |
2023-08-13 |
Not clear |
| Thomas Fors. Lixisenatide as add-on to insulin glargine for the treatment of type 2 diabetes mellitus. Expert opinion on pharmacotherapy. vol 17. issue 12. 2017-02-22. PMID:27341040. |
glp-1 ras, such as lixisenatide, and basal insulin offer complementary mechanisms of action in their ability to provide glycemic control, thus providing a strong rationale for using them in combination with each other for the treatment of t2dm. |
2017-02-22 |
2023-08-13 |
Not clear |
| Fabien Plisson, Timothy A Hill, Justin M Mitchell, Huy N Hoang, Aline D de Araujo, Weijun Xu, Adam Cotterell, David J Edmonds, Robert V Stanton, David R Derksen, Paula M Loria, David A Griffith, David A Price, Spiros Liras, David P Fairli. Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling. European journal of medicinal chemistry. vol 127. 2017-02-21. PMID:27823886. |
helixconstraints and amino acid substitution in glp-1 increase camp and insulin secretion but not beta-arrestin 2 signaling. |
2017-02-21 |
2023-08-13 |
Not clear |